Amgen (AMGN) Accounts Payables (2009 - 2026)

Amgen's Accounts Payables history runs 18 years deep, the most recent figure standing at $2.9 billion for Q1 2026.

• In Q1 2026, Accounts Payables rose 21.99% year-over-year to $2.9 billion; the TTM figure through Mar 2026 stood at $2.9 billion (up 21.99% YoY), while the FY2025 annual figure was $2.4 billion, up 24.06% from the prior year.
• Accounts Payables was $2.9 billion for Q1 2026 at Amgen, up from $2.4 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $3.0 billion in Q2 2025 to a low of $1.2 billion in Q3 2022.
• Historically, Accounts Payables has averaged $1.9 billion across 5 years, with a median of $1.6 billion in 2024.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables fell 5.92% in 2023, then jumped 87.05% in 2024.
• A 5-year view of Accounts Payables shows it stood at $1.6 billion in 2022, then increased by 1.15% to $1.6 billion in 2023, then gained by 20.0% to $1.9 billion in 2024, then climbed by 24.06% to $2.4 billion in 2025, then increased by 24.0% to $2.9 billion in 2026.
• The last three Accounts Payables figures came in at $2.9 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.8 billion (Q3 2025), per Business Quant data.